- Home
- EVN vs LYEL Comparison
EVN vs LYEL Comparison
Compare EVN & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVN | LYEL |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.3M | 369.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EVN | LYEL |
|---|---|---|
| Price | $10.90 | $33.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 101.2K | 61.1K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.94 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.64 | $7.65 |
| 52 Week High | $10.45 | $35.16 |
Technical Indicators
Market Signals| Indicator | EVN | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 74.82 |
| Support Level | $10.82 | $20.59 |
| Resistance Level | $11.18 | $35.16 |
| Average True Range (ATR) | 0.11 | 2.58 |
| MACD | -0.00 | 0.89 |
| Stochastic Oscillator | 2.82 | 87.81 |
Price Performance
Historical ComparisonAbout EVN Eaton Vance Municipal Income Trust
Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.